Dr. May on Olaratumab Activity in Pediatric Bone and Soft Tissue Sarcoma

Caitlin May, MD
Published: Friday, Jan 20, 2017



Caitlin May, PhD, postdoctoral research fellowship at Eli Lilly and Company, discusses olaratumab's (Lartruvo) demonstrating anti-tumor activity in models of pediatric bone and soft-tissue sarcoma.

In the patient and cell derived xenograft models, olaratumab is seeing the most activity in osteosarcoma and rhabdoid tumor, explains May. When combined with cisplatin, there is an enhancement of activity, but more research must be done.

According to May, oncologists are still trying to better understand the mechanism of action and why olaratumab is advantageous in the preclinical setting. The next step for researchers is going to be looking at different models and the genetic landscape.
 


Caitlin May, PhD, postdoctoral research fellowship at Eli Lilly and Company, discusses olaratumab's (Lartruvo) demonstrating anti-tumor activity in models of pediatric bone and soft-tissue sarcoma.

In the patient and cell derived xenograft models, olaratumab is seeing the most activity in osteosarcoma and rhabdoid tumor, explains May. When combined with cisplatin, there is an enhancement of activity, but more research must be done.

According to May, oncologists are still trying to better understand the mechanism of action and why olaratumab is advantageous in the preclinical setting. The next step for researchers is going to be looking at different models and the genetic landscape.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Moving Forward From the Status Quo for the Treatment of Soft Tissue Sarcoma: Key Questions & New Answers to Optimize OutcomesAug 16, 20181.5
Clinical Interchange™: Moving Forward From the Status Quo for the Treatment of Soft Tissue Sarcoma: Key Questions and New Answers to Optimize OutcomesOct 31, 20182.0
Publication Bottom Border
Border Publication
x